BlueCrest Capital Management’s XBiotech XBIT Stock Holding History

BlueCrest Capital Management’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-27,500	Closed	-$303K	–	1066
2019 Q1	$303K	Buy	+27,500	New	+$223K	0.01%	704
2018 Q4	–	Sell	-26,858	Closed	-$85K	–	1464
2018 Q3	$85K	Buy	26,858 +8,428	+46%	+$32.8K	﹤0.01%	1403
2018 Q2	$83K	Buy	+18,430	New	+$83.3K	﹤0.01%	1408

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

BlueCrest Capital Management's XBIT Position: Q2 2019 in Review

BlueCrest Capital Management sold out of XBiotech (XBIT) in Q2 2019, closing a stake of 27,500 shares — an estimated $303K sold.

BlueCrest Capital Management first reported a position in XBIT in Q2 2018 and held it in 3 quarters. The position peaked at $303K in Q1 2019. 43 funds tracked by Wall St. Rank hold XBIT as of Q2 2019.

BlueCrest Capital Management reported no remaining XBiotech position as of Q2 2019 after selling out during the quarter.
BlueCrest Capital Management sold 27,500 XBiotech shares in Q2 2019, an estimated $303K.
BlueCrest Capital Management first reported a position in XBiotech in Q2 2018 and held it in 3 quarters.
BlueCrest Capital Management's XBiotech position peaked at $303K in Q1 2019.
43 funds tracked by Wall St. Rank held XBiotech as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.